Church RJ, et al. - Given that current blood biomarkers are suboptimal in the detection and prediction of drug-induced liver injury (DILI), investigators tried to characterize the natural variability and performance characteristics of 14 promising DILI biomarker candidates. Using the Model for End-Stage Liver Disease, researchers analyzed serum or plasma from multiple cohorts of healthy volunteers and DILI patients for microRNA-122 (miR-122), glutamate dehydrogenase (GLDH), total cytokeratin 18 (K18), caspase cleaved K18, glutathione S-transferase α, alpha-fetoprotein, arginase-1, osteopontin (OPN), sorbitol dehydrogenase, fatty acid binding protein, cadherin-5, macrophage colony-stimulating factor receptor (MCSFR), paraoxonase 1 (normalized to prothrombin protein), and leukocyte cell-derived chemotaxin-2. Findings suggested that GLDH seems to be more useful than miR-122 in the identification of DILI patients, and K18, OPN and MCSFR are promising candidates for prognosis prediction during an acute DILI event.